C:\Program Files\Stnexp\Queries\09552969.str





chain nodes :
14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
12-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13 12-14
14-15

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:CLASS 15:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:23:57 ON 23 MAY 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:24:09 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9
DICTIONARY FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09552969.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 17:24:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 235 TO ITERATE

100.0% PROCESSED 235 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3781 TO 5619
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 17:24:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4396 TO ITERATE

100.0% PROCESSED 4396 ITERATIONS 90 ANSWERS
SEARCH TIME: 00.00.01

L3 90 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 17:24:43 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 22 May 2003 (20030522/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Title compds. [I; X = NR2YLZ, NH; X1 = CH2, CO; dotted bonds = single, double; R1 = H, OH, Cl, F, I, Br, alkyl alkoxy, (un)substituted phenyl; R3 = alkyl, cycloalkyl, naphthyl, heteroaryl, (un)substituted phenyl; n = 0, 1, 2; R2 = H, alkyl; Y = CH2, CO; L = alkylene, cycloalkylene, arylclkylene, (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl, (N-methylene)piperidin-4,4-diyl; Z = (un)substituted Ph, N-sulfonamido, N-(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl], enantiomers, diastereomers, and pharmaceutically acceptable salts are prepd. as such are useful in the treatment of obesity, eating disorders, anorexia nervosa, bulimia nervosa, diabetes, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression or anxiety and disorders of the central nervous system. Pharmaceutical compn. comprising therapeutically effective amt. of title compds. and pharmaceutically acceptable carrier and method of treating disorders and diseases assocd. with NPY receptor subtype Y5 comprising administering to a mammal are claimed. Thus, the title compd. II was prepd. and tested for the human NPY Y5 receptor binding affinity.

ACCESSION NUMBER: 2000:814460 CAPLUS
DOCUMENT NUMBER: 133:350139
TITLE: Preparation of 3a,4,5,9b-tetrahydro-1H-benzo[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and disorders of CNS
INVENTOR(S): Dax, Scott; Mcnally, James
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000068197	A1	20001116	WO 2000-US10981	20000420

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1177172	A1	20020206	EP 2000-928340	20000420

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-132660P P 19990505
WO 2000-US10981 W 20000420

OTHER SOURCE(S): MARPAT 133:350139

IT **263843-85-2P 263843-86-3P 263843-88-5P**
306299-03-6P 306299-04-7P 306299-05-8P
306299-10-5P 306299-11-6P 306299-12-7P
306299-28-5P 306299-33-2P 306299-36-5P
306299-37-6P 306299-77-4P 306299-79-6P
306299-80-9P 306299-81-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydrobenzo[e]indoly-2-ylamines as NPY Y5 receptor subtype useful for obesity, eating, sleep, sexual, and depression disorders)

RN 263843-85-2 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-86-3 CAPLUS

CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-88-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 306299-03-6 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-04-7 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-05-8 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-10-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-11-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-12-7 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-28-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-7-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-33-2 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-36-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-37-6 CAPLUS

CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-77-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 306299-36-5
CMF C27 H33 N5 O2

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 306299-79-6 CAPLUS
CN Cyclohexanecarboxamide, N-[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-[[(phenylsulfonyl)amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-80-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-81-0 CAPLUS
CN Cyclohexanecarboxamide, N-[(3aR,9bS)-7-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-[[(phenylsulfonyl)amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **306299-35-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of tetrahydrobenzo[e]indoly-2-ylamines as NPY Y5 receptor subtype useful for obesity, eating, sleep, sexual, and depression disorders)
RN 306299-35-4 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **306299-06-9P 306299-07-0P 306299-08-1P**
306299-09-2P 306299-13-8P 306299-14-9P
306299-15-0P 306299-16-1P 306299-17-2P
306299-18-3P 306299-19-4P 306299-20-7P
306299-21-8P 306299-22-9P 306299-23-0P
306299-24-1P 306299-26-3P 306299-29-6P
306299-30-9P 306299-31-0P 306299-32-1P
306299-34-3P 306299-38-7P 306299-39-8P
306299-40-1P 306299-41-2P 306299-42-3P
306299-43-4P 306299-44-5P 306299-45-6P
306299-46-7P 306299-47-8P 306299-48-9P
306299-49-0P 306299-50-3P 306299-51-4P
306299-52-5P 306299-53-6P 306299-54-7P
306299-55-8P 306299-56-9P 306299-57-0P
306299-58-1P 306299-59-2P 306299-60-5P

306299-61-6P 306299-62-7P 306299-63-8P
306299-64-9P 306299-65-0P 306299-66-1P
306299-67-2P 306299-68-3P 306299-69-4P
306299-70-7P 306299-71-8P 306299-72-9P
306299-73-0P 306299-74-1P 306299-75-2P
306299-76-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydrobenzo[e]indoly-2-ylamines as NPY Y5 receptor subtype useful for obesity, eating, sleep, sexual, and depression disorders)

RN 306299-06-9 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-07-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dihydroxy-1H-benz[e]indol-2-yl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-08-1 CAPLUS
CN Cyclohexanecarboxamide, N-[(3aR,9bS)-7,8-difluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-[[[(2-nitrophenyl)sulfonyl]amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-09-2 CAPLUS
CN Cyclohexanecarboxamide, N-[(3aR,9bS)-7-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-[[[(2,4-dichlorophenyl)sulfonyl]amino]methyl]-, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-13-8 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-14-9 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-15-0 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-16-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-7,8-difluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-2-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-17-2 CAPLUS
CN Benzenesulfonamide, 2,6-difluoro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-18-3 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dihydroxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-19-4 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-20-7 CAPLUS
CN 1-Naphthalenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-21-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-22-9 CAPLUS
CN Benzenesulfonamide, 2-methoxy-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-23-0 CAPLUS
CN Benzenesulfonamide, 2-nitro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-

7-nitro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-24-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-9-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-26-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-8-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-29-6 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-6-chloro-3a,4,5,9b-tetrahydro-

1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-30-9 CAPLUS
CN Benzenesulfonamide, N-[7-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]heptyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-31-0 CAPLUS
CN Benzenesulfonamide, N-[4-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]-2-butynyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-32-1 CAPLUS
CN Benzenesulfonamide, 3,4-dimethoxy-N-[[trans-4-[[methyl[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dimethoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-34-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-38-7 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-39-8 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dihydroxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-40-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dihydroxy-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-41-2 CAPLUS
CN 1-Piperidineacetamide, N-[(3aR,9bS)-7,8-difluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-42-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[2-[[(3aR,9bS)-7,8-difluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-1,3-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-43-4 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-44-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[2-[[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-1,3-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-45-6 CAPLUS
CN 1H-Benzimidazole-1-hexanamide, 2,3-dihydro-2-oxo-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-46-7 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[6-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]hexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-47-8 CAPLUS
CN 1-Piperidineacetamide, N-[(3aR,9bS)-7-bromo-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-(2,3-dihydro-5,6-dimethyl-2-oxo-1H-benzimidazol-1-yl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-48-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[2-[[(3aR,9bS)-7-bromo-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-1,3-dihydro-5,6-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-49-0 CAPLUS
CN 1-Piperidineacetamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dimethoxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-50-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dimethoxy-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-51-4 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-acetamide, 4-oxo-1-phenyl-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-52-5 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 1-phenyl-8-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-53-6 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-acetamide, 4-oxo-1-phenyl-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-54-7 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 1-phenyl-8-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-55-8 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-acetamide, 4-oxo-1-phenyl-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-56-9 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 1-phenyl-8-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-57-0 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-58-1 CAPLUS
CN 1H-Benz[e]indol-2-amine, 3a,4,5,9b-tetrahydro-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-59-2 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-60-5 CAPLUS
CN 1H-Benz[e]indol-2-amine, 3a,4,5,9b-tetrahydro-7-methoxy-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-61-6 CAPLUS
CN 1-Piperidineacetamide, 4-[(phenylsulfonyl)amino]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-62-7 CAPLUS
CN Benzenesulfonamide, N-[1-[2-[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]ethyl]-4-piperidinyl]-, rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.



RN 306299-63-8 CAPLUS
CN 1H-Benz[e]indole-7,8-diol, 3a,4,5,9b-tetrahydro-2-[[2-[4-(2-methoxyphenyl)-1-piperidinyl]ethyl]amino]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-64-9 CAPLUS
CN 1-Piperazineacetamide, N-[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-(2-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-65-0 CAPLUS
CN 1H-Benz[e]indol-2-amine, 7-fluoro-3a,4,5,9b-tetrahydro-N-[2-[4-(2-

methoxyphenyl)-1-piperazinyl]ethyl]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-66-1 CAPLUS
CN 1-Piperazineacetamide, N-[(3aR,9bS)-7,8-difluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-(2-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-67-2 CAPLUS
CN 1H-Benz[e]indol-2-amine, 7,8-difluoro-3a,4,5,9b-tetrahydro-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-68-3 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dihydroxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-69-4 CAPLUS
CN 1H-Benz[e]indole-7,8-diol, 3a,4,5,9b-tetrahydro-2-[[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]amino]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-70-7 CAPLUS
CN 1-Piperazineacetamide, 4-(2-methoxyphenyl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7,8-dimethoxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-71-8 CAPLUS
CN 1H-Benz[e]indol-2-amine, 3a,4,5,9b-tetrahydro-7,8-dimethoxy-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-72-9 CAPLUS
CN 1-Piperazineacetamide, 4-(2-hydroxyphenyl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-73-0 CAPLUS
CN 1H-Benz[e]indol-7-ol, 3a,4,5,9b-tetrahydro-2-[[2-[4-(2-hydroxyphenyl)-1-piperazinyl]ethyl]amino]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-74-1 CAPLUS
CN 1-Piperazineacetamide, 4-(2-nitrophenyl)-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-75-2 CAPLUS
CN 1H-Benz[e]indol-7-ol, 3a,4,5,9b-tetrahydro-2-[[2-[4-(2-nitrophenyl)-1-piperazinyl]ethyl]amino]-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 306299-76-3 CAPLUS
CN 1H-Benz[e]indol-7-ol, 2-[[2-[4-(2-fluorophenyl)-1-piperazinyl]ethyl]amino]-3a,4,5,9b-tetrahydro-, (3aR,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB (3A,4,5,9b-Tetrahydro-1H-benz[e]indol-2-yl)amines were prepd. via reductive amination and concomitant cyclization of .alpha.-cyanomethyl-.beta.-aminotetralins. N-acylation with .OMEGA.-sulfonamido-carboxylic acids and subsequent redn. afforded a series of title compds., e.g., I (Y = CO, CH2), which bound to the human neuropeptide Y Y5 receptor with nanomolar affinity.

ACCESSION NUMBER: 2000:146875 CAPLUS
DOCUMENT NUMBER: 132:279085
TITLE: N-(Sulfonamidoalkyl)(tetrahydro-1H-benz[e]indol-2-yl)amines: potent antagonists of human neuropeptide Y Y5 receptor
AUTHOR(S): McNally, James J.; Youngman, Mark A.; Lovenberg, Timothy W.; Nepomuceno, Diane H.; Wilson, Sandy J.; Dax, Scott L.
CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(3), 213-216
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **263843-82-9P 263843-83-0P 263843-84-1P**
263843-85-2P 263843-86-3P 263843-87-4P
263843-88-5P 263843-89-6P 263843-90-9P
263843-91-0P 263843-92-1P 263843-93-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and neuropeptide Y5 receptor binding affinity of)
RN 263843-82-9 CAPLUS
CN Acetamide, N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 263843-83-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-84-1 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



HCl

RN 263843-85-2 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-86-3 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-87-4 CAPLUS
CN Cyclohexanecarboxamide, 4-[[(phenylsulfonyl)amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-88-5 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-hydroxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-89-6 CAPLUS
CN Cyclohexanecarboxamide, N-[(3aR,9bS)-7-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-4-[[(phenylsulfonyl)amino]methyl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-90-9 CAPLUS
CN Benzenesulfonamide, N-[[trans-4-[[[(3aR,9bS)-7-chloro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-91-0 CAPLUS
CN Cyclohexanecarboxamide, 4-[[[(2-fluorophenyl)sulfonyl]amino]methyl]-N-[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]-, monohydrochloride, trans-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-92-1 CAPLUS
CN Benzenesulfonamide, 2-fluoro-N-[[trans-4-[[[(3aR,9bS)-3a,4,5,9b-tetrahydro-7-methoxy-1H-benz[e]indol-2-yl]amino]methyl]cyclohexyl]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 263843-93-2 CAPLUS
CN Hexanamide, 2-amino-6-[[(2-fluorophenyl)sulfonyl]amino]-N-[(3aR,9bS)-7-fluoro-3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
GI



I

AB The crystal structure of the (methylimino)azaandrostanone hydrochloride I was detn. and related to GABA-A receptor antagonist activity.

ACCESSION NUMBER: 1991:680360 CAPLUS
DOCUMENT NUMBER: 115:280360
TITLE: Crystal structure of R 29490, an N-methylated analog of a potent steroidic GABA-A antagonist: 3.alpha.-hydroxy-16-imino-5.beta.-17-azaandrostan-11-one, R 5135
AUTHOR(S): Boulanger, Thierry; Vercauteren, Daniel P.; Evrard, Guy; Durant, Francois
CORPORATE SOURCE: Lab. Chim. Mol. Struct., Fac. Univ. Notre-Dame de la Paix, Namur, B-5000, Belg.
SOURCE: Bulletin des Societes Chimiques Belges (1991), 100(7), 517-19
CODEN: BSCBAG; ISSN: 0037-9646
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **137548-55-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(crystal structure and GABA-A antagonist activity of)
RN 137548-55-1 CAPLUS
CN 10H-Naphth[2,1-e]indol-10-one, 3,3a,3b,4,5,5a,6,7,8,9,9a,9b,11,11a-tetradecahydro-7-hydroxy-9a,11a-dimethyl-2-(methylamino)-, monohydrochloride, (3aS,3bS,5aR,7R,9aS,9bS,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **137548-58-4**
RL: PRP (Properties)
(mol. structure of)
RN 137548-58-4 CAPLUS
CN 10H-Naphth[2,1-e]indol-10-one, 3,3a,3b,4,5,5a,6,7,8,9,9a,9b,11,11a-tetradecahydro-7-hydroxy-9a,11a-dimethyl-2-(methylamino)-, (3aS,3bS,5aR,7R,9aS,9bS,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 17:23:57 ON 23 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 17:24:09 ON 23 MAY 2003
L1             STRUCTURE UPLOADED
L2           4 S L1
L3          90 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 17:24:43 ON 23 MAY 2003
L4           3 S L3

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    14.03     162.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.95      -1.95

STN INTERNATIONAL LOGOFF AT 17:25:21 ON 23 MAY 2003
```